BRIEF-ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Reuters
Mar 09
BRIEF-ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 9 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:

  • ARS PHARMACEUTICALS Q4 EPS USD -0.42

  • ARS PHARMACEUTICALS Q4 NET INCOME USD -41.3 MILLION

  • ARS PHARMACEUTICALS Q4 REVENUE USD 28.1 MILLION VERSUS. IBES ESTIMATE USD 25.6 MILLION

  • ARS PHARMACEUTICALS INC - ARS PHARMA TO EXPAND SALES FORCE FROM 106 TO 150 BEGINNING Q2 2026

  • ARS PHARMACEUTICALS INC - REGULATORY APPROVAL FOR NEFFY IN CANADA EXPECTED Q2 2026, LAUNCH EXPECTED LATER IN 2026

Source text: ID:nGNX6dbN79

Further company coverage: SPRY.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10